FY2026 EPS Estimates for GH Research Boosted by Analyst

Key Points

• HC Wainwright raised its FY2026 EPS estimate for GH Research to a loss of $1.14 per share from $1.21 and maintained a Buy rating. The revised forecast remains above the broader consensus loss estimate of $1.33.
• GH Research reported a quarterly loss of $0.23 per share, beating the consensus estimate of a $0.29 loss by $0.06. Other analysts have also issued favorable views, contributing to a consensus “Moderate Buy” rating and a $45 price target.
• Despite improved estimates, GH Research remains a clinical-stage biotechnology company with projected losses through FY2030. Its shares opened at $29.08, while institutional investors own approximately 56.9% of the stock.

GH Research PLC (NASDAQ:GHRS - Free Report) - Investment analysts at HC Wainwright increased their FY2026 earnings estimates for shares of GH Research in a research report issued to clients and investors on Monday, August 10th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.14) per share for the year, up from their previous estimate of ($1.21). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for GH Research's current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for GH Research's Q4 2026 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.42) EPS, Q4 2027 earnings at ($0.46) EPS, FY2027 earnings at ($1.62) EPS, FY2028 earnings at ($1.76) EPS, FY2029 earnings at ($2.11) EPS and FY2030 earnings at ($1.22) EPS.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.06.

A number of other research analysts have also recently commented on GHRS. Cantor Fitzgerald upped their price objective on GH Research from $35.00 to $40.00 and gave the company an "overweight" rating in a report on Friday, August 7th. New Street Research set a $65.00 target price on GH Research in a research report on Monday. Wells Fargo & Company started coverage on GH Research in a research note on Monday, July 27th. They issued an "overweight" rating and a $44.00 price target on the stock. Needham & Company LLC increased their price target on GH Research from $32.00 to $39.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Finally, Citigroup reissued an "outperform" rating on shares of GH Research in a research report on Friday, May 15th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, GH Research presently has a consensus rating of "Moderate Buy" and a consensus price target of $45.00.

GH Research Price Performance

NASDAQ:GHRS opened at $29.08 on Wednesday. The company's 50-day moving average is $25.88 and its two-hundred day moving average is $20.37. GH Research has a 1-year low of $11.80 and a 1-year high of $31.44. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -29.08 and a beta of 1.29.

Institutional Trading of GH Research

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GHRS. JPMorgan Chase & Co. acquired a new position in GH Research during the second quarter worth $79,000. BNP Paribas Financial Markets grew its stake in shares of GH Research by 165.4% in the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company's stock valued at $207,000 after buying an additional 10,600 shares in the last quarter. Osaic Holdings Inc. grew its stake in shares of GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company's stock valued at $75,000 after buying an additional 2,400 shares in the last quarter. UBS Group AG raised its holdings in shares of GH Research by 11.5% in the 3rd quarter. UBS Group AG now owns 511,464 shares of the company's stock valued at $7,314,000 after buying an additional 52,882 shares during the period. Finally, Lynx1 Capital Management LP raised its holdings in shares of GH Research by 27.5% in the 3rd quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company's stock valued at $122,997,000 after buying an additional 1,854,238 shares during the period. Hedge funds and other institutional investors own 56.90% of the company's stock.

GH Research News Summary

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and raised its FY2026 EPS forecast to a loss of $1.14 from a loss of $1.21. The firm also improved its FY2027 estimate to a loss of $1.62 from $1.64, indicating expectations for somewhat lower losses than previously projected.
• Positive Sentiment: The analyst raised quarterly EPS forecasts for Q4 2026, Q2 2027, Q3 2027 and Q4 2027 by $0.01 each, to losses of $0.31, $0.38, $0.42 and $0.46, respectively. These revisions may support GHRS by signaling improved cost or development-spending expectations.
• Neutral Sentiment: HC Wainwright initiated longer-term estimates calling for losses of $1.76 per share in FY2028, $2.11 in FY2029 and $1.22 in FY2030. The forecasts provide a valuation framework but do not imply near-term profitability.
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from July 27, with a zero-day days-to-cover ratio. The data offers no indication of meaningful short-selling pressure or potential short-covering demand, though the reported figures appear unusual.
• Negative Sentiment: GH Research is still expected to post a current-year loss of approximately $1.33 per share, and all of HC Wainwright’s published forecasts through FY2030 remain negative. Investors therefore continue to depend on clinical and commercial progress rather than current earnings.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm's lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source